Press Releases

Cerevance Appoints Ottavio V. Vitolo, M.D., as Chief Medical Officer

Boston, MA – October 3, 2022 – Cerevance, a private, clinical-stage drug discovery and development
company focused on central nervous system (CNS) diseases, today announced the appointment of
Ottavio V. Vitolo, M.D. as chief medical officer. Dr. Vitolo brings more than 20 years of experience in
neuroscience research and drug development. He joins Cerevance to lead the global clinical
development and regulatory operations.

“We are thrilled to welcome Ottavio whose expertise will help advance our broad portfolio of innovative
treatments for neurodegenerative diseases,” said Craig Thompson, chief executive officer of Cerevance.
“His diverse and extensive experience in translational and clinical research will be an invaluable asset as
we strategically advance our pipeline into and through the clinic.”

Dr. Vitolo most recently served as chief medical officer and global head of R&D at Alcyone Therapeutics.
Prior to this position, Dr. Vitolo served as senior vice president, head of R&D and chief medical officer at
Relmada Therapeutics Inc. While at Relmada, he critically contributed to the company’s growth and
strategy, including leading the successful initiation and completion of dextromethadone clinical studies.
Earlier in his career, Dr. Vitolo was vice president of clinical development at Homology Medicines and
held positions of increasing responsibilities at Pfizer, including senior director and head of
neuromuscular clinical research, research project lead, global clinical lead and medical director in the
neuroscience research unit.

Dr. Vitolo is a trained and practicing neuropsychiatrist. After receiving his medical degree from the
University of Rome La Sapienza, he completed his psychiatry residency at Washington University in St.
Louis and completed a fellowship in behavioral neurology and neuropsychiatry at Brigham and Women’s
Hospital and Massachusetts General Hospital. Dr. Vitolo also has a Master of Medical Sciences degree
from Harvard Medical School.

Dr. Vitolo stated, “I am delighted to join Cerevance at such a pivotal time in the company’s history. The
potential of the NETSseq target discovery platform combined with the broad pipeline creates a
tremendous opportunity to bring several novel and potentially transformative therapies to patients.”

About Cerevance
Cerevance is a private pharmaceutical company whose lead therapeutic, CVN424, a first-in-class, oral,
non-dopaminergic compound acting on a novel target (GPR6), recently demonstrated significant and
clinically meaningful efficacy in a 135-patient Phase 2 study in patients with Parkinson’s disease. The
company uses its proprietary NETSseq technology platform to highly selectively identify novel target
proteins that are either over- or under-expressed in diseased brains. Partnering with over 20 brain banks
and evaluating more than 11,000 human post-mortem brain tissue samples, Cerevance is advancing a
robust pipeline of targeted treatments for patients with neurodegenerative diseases, including
Parkinson’s disease and Alzheimer’s disease. For additional information, please visit
www.cerevance.com.

Contacts

Cerevance:
Johnna Simoes, ir@cerevance.com

Media:
Andrew Mielach, amielach@lifescicomms.com, +1-646-876-5868

Back to Press Releases